Paion AG Stock
Heavy losses for Paion AG today as the stock fell by -€0.036 (-4.830%).
With 1 Sell predictions and 0 Buy predictions the community sentiment towards the Paion AG stock is not clear.
For the coming years our community has positive and negative things to say abot the Paion AG stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Paion AG in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Paion AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Paion AG | -4.830% | -15.329% | -23.568% | -60.056% | -41.474% | -68.578% | -74.319% |
| B.R.A.I.N. Biotechnology Research and Information Network AG | -9.620% | -16.606% | -33.811% | -53.707% | -49.119% | -59.756% | -76.618% |
| MagForce AG | 32.450% | -49.091% | -74.154% | -98.930% | -98.765% | -99.232% | -99.576% |
| Affimed N.V. | -4.870% | 1.118% | -23.968% | -58.710% | -57.234% | -28.976% | - |
Comments
News
DGAP-News: PAION AG reports financial results for the first half-year 2022
DGAP-News: PAION AG reports financial results for the first half-year 2022
DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DGAP-News: PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE
DGAP-News: PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE
